

**NRG-HN004 Data Dictionary for NCT03258554-D4-Dataset.csv**

Note #1: This is the dataset for the lead-in phase analysis. There is one record per subject.

Note #2: Data are as of October 17, 2019.

Note #3: Includes lead-in phase subjects.

Note #4: Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning).

See also the companion datasets and data dictionaries:

NCT03258554-D1-Dataset.csv and NCT03258554-D1-Data-Dictionary.pdf

NCT03258554-D2-Dataset.csv and NCT03258554-D2-Data-Dictionary.pdf

NCT03258554-D3-Dataset.csv and NCT03258554-D3-Data-Dictionary.pdf

#	Variable	Description	Coding
1	study_no	Study number	Character
2	deident_subjectid	De-identified subject ID	Character
3	rx	Assigned treatment	5=Dose level 1 RT+Durvalumab
4	age_c	Age (years)	Character
5	gender	Gender	1=Male
			2=Female
6	race	Race	5=White
7	ethnicity	Ethnicity	2=Not Hispanic or Latino
8	zubrod	Zubrod performance status	Continuous
9	pack_years	Smoking history: pack-years	Continuous
10	primary_site_p16_grp	Primary site	1=Oropharynx, p16-positive
			3=Oropharynx, p16-negative
			7=Larynx
11	t_stage_clinical_ajcc7	T stage, clinical (AJCC 7)	1=T1
			2=T2
			3=T3
			4=T4
12	n_stage_clinical_ajcc7	N stage, clinical (AJCC 7)	1=N1
			3=N2b
			4=N2c
13	m_stage_clinical_ajcc7	M stage, clinical (AJCC 7)	0=M0
14	comorb_group	Comorbidity group	1=Absolute or relative contraindication to cisplatin

#	Variable	Description	Coding
			2=Age >= 70 with moderate to severe comorbidity or vulnerability to cisplatin
			3=Age < 70 with severe comorbidity or vulnerability to cisplatin
15	comorb_number	Number of comorbidity conditions	Continuous
16	rt_reason_term_text	RT off treatment reason	Character
17	rt_dose	RT dose (Gy)	Continuous
18	rt_fx	RT fractions	Continuous
19	rt_elapsed_days	RT elapsed days	Continuous
20	rt_type	RT type	Character
21	rt_modality	RT modality	Character
22	durvalumab_reason_term_text	Durvalumab off treatment reason	Character
23	durvalumab_doses	Durvalumab number of doses	Continuous
24	durvalumab_dose_mg	Durvalumab total dose (mg)	Continuous
25	dlt	Dose-limiting toxicity (DLT)	1=No
26	ae_grade5	Grade 5 adverse events	Character
27	ae_grade4	Grade 4 adverse events	Character
28	ae_grade3_related_durva	Grade 3 adverse events related to durvalumab	Character